Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.
Frequently asked questions
What sector does Kardigan, Inc. Common Stock (KARD) operate in?
Kardigan, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kardigan, Inc. Common Stock (KARD) current stock price?
As of the latest data, Kardigan, Inc. Common Stock stock price is $13.60, with a previous close of $12.63. Kardigan, Inc. Common Stock gained $0.97 in the last trading session, representing a 7.68% increase.
What is Kardigan, Inc. Common Stock (KARD) current market capitalization?
Kardigan, Inc. Common Stock market cap is approximately 1.27 billion.
What is Kardigan, Inc. Common Stock (KARD) Earnings Per Share (EPS)?
The trailing EPS is -$3.09, and the forward EPS is -$3.20.
What is Kardigan, Inc. Common Stock (KARD) EBITDA?
Kardigan, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -73.04 million.
Does Kardigan, Inc. Common Stock (KARD) pay dividends?
No. Kardigan, Inc. Common Stock does not pay a dividend.
When is Kardigan, Inc. Common Stock (KARD) next earnings report?
Kardigan, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Kardigan, Inc. Common Stock (KARD) beta (volatility) score?
Kardigan, Inc. Common Stock has a beta of 0.002, indicating lower volatility than the overall market.
